ADHD Stimulants and Pregnancy: New Study Examines Risks of Continued Treatment
A large claims-based study found no increased risk for most outcomes with first-trimester stimulant exposure during pregnancy, but higher risks when use continued later in pregnancy.
Lamotrigine and Menopausal Hormone Therapy: What Women Need to Know
Estrogen-containing menopausal hormone therapy (MHT) may lower blood levels of lamotrigine, potentially reducing its effectiveness in some women with bipolar disorder. What do we know about this interaction, and does the risk differ with oral, transdermal, or vaginal estrogen?
Lithium Use in Pregnancy and the Risk of Adverse Perinatal Outcomes
A new cohort study from Australia found that lithium use during pregnancy was linked to a two-fold increased risk of spontaneous preterm birth, along with higher risks of a large for gestational age infant and congenital cardiac malformations. We review how these findings compare with prior research and what they mean for women with bipolar disorder who are using — or considering — lithium during pregnancy.
Weekly Roundup for August 14, 2026: Recent Publications in Women’s Mental Health
This week’s roundup examines medication safety in pregnancy, postpartum depression treatments, opioid and cannabis use, and emerging research on women’s ADHD.
New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine
New prospective data on 56 first-trimester vortioxetine exposures found no major malformations, offering reassuring but still preliminary reproductive safety information.
Weekly Roundup for August 7, 2026: Recent Publications in Women’s Mental Health
This week’s roundup discusses the impact of hormonal contraception on mood and covers new data on the use of ADHD medications, antidepressants, and antipsychotics during pregnancy.